Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter

Vaccine

Volumn 34, Issue 1, 2016, Pages 49-55

  Alharbi, Naif Khalaf ^a,b   Spencer, Alexandra J ^a   Salman, Ahmed M ^a   Tully, Claire M ^a   Chinnakannan, Senthil k ^a   Lambe, Teresa ^a   Yamaguchi, Yuko ^a   Morris, Susan J ^a   Orubu, Toritse ^a   Draper, Simon J ^a   Hill, Adrian V S ^a   Gilbert, Sarah C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Immunogenicity; MVA; Promoter; Transgene expression; Vaccine development; Viral vector

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; THYMIDINE KINASE; DRUG CARRIER; GAMMA INTERFERON; INFLUENZA VACCINE; MALARIA VACCINE; RECOMBINANT VACCINE;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROMOTER REGION; RENILLA RENIFORMIS; SCANNING ELECTRON MICROSCOPY; TRANSGENE; ANIMAL; BAGG ALBINO MOUSE; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; MONONUCLEAR CELL; SECRETION (PROCESS); TREATMENT OUTCOME; VACCINIA VIRUS;

ANIMALS; DRUG CARRIERS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; GENETIC VECTORS; INFLUENZA VACCINES; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALARIA VACCINES; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; TRANSGENES; TREATMENT OUTCOME; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84949725547     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.11.028     Document Type: Article

References (27)

1. Sutter G., Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 2003, 3(3):263-271.
2. Gomez C.E., et al. Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccine Immunother 2012, 8(9):1192-1207.
3. Gilbert S.C. Clinical development of Modified Vaccinia virus Ankara vaccines. Vaccine 2013, 31(39):4241-4246.
4. Volz A., Sutter G. Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies. Vaccine 2013, 31(39):p4235-p4240.
5. Stanley D.A., et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med 2014, 20(10):1126-1129.
6. Hill A.V., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010, 6(1):78-83.
7. Gilbert S.C., et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006, 24(21):4554-4561.
8. Garcia-Arriaza J., Esteban M. Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccine Immunother 2014, 10(8):p2235-p2244.
9. Wyatt L.S., et al. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996, 14(15):1451-1458.
10. Chakrabarti S., Sisler J.R., Moss B. Compact: synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 1997, 23(6):1094-1097.
11. Hammond J.M., Oke P.G., Coupar B.E. A synthetic vaccinia virus promoter with enhanced early and late activity. J Virol Methods 1997, 66(1):135-138.
12. Orubu T.et al. Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS ONE 2012, 7(6):e40167.
13. Broyles S.S. Vaccinia virus transcription. J Gen Virol 2003, 84(Pt 9):2293-2303.
14. Hopkins R.et al. Dual neonate vaccine platform against HIV-1 and M. tuberculosis. PLoS ONE 2011, 6(5):e20067.
15. Wang Z., et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 2010, 28(6):1547-1557.
16. Coupar B.E., et al. Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol 1986, 16(12):1479-1487.
17. Bronte V., et al. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA 1997, 94(7):3183-3188.
18. Oseroff C., et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 2005, 102(39):13980-13985.
19. Tscharke D.C., et al. Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005, 201(1):95-104.
20. El Omari K., et al. Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. BMC Struct Biol 2006, 6:22.
21. Cottingham M.G.et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 2008, 3(2):e1638.
22. Berthoud T.K., et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine: MVA-NP+M1. Clin Infect Dis 2011, 52(1):1-7.
23. Moorthy V.S., et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens: including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004, 189(12):2213-2219.
24. Ewer K.J., et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 2013, 4:2836.
25. Tameris M.D., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381(9871):1021-1028.
26. Yang Z., et al. Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci USA 2010, 107(25):11513-11518.
27. Assarsson E., et al. Kinetic analysis of a complete poxvirus transcriptome reveals an immediate-early class of genes. Proc Natl Acad Sci USA 2008, 105(6):2140-2145.